FDA investigates reports of hair loss, suicidal thoughts in people using popular diabetes, weight loss drugs

The Food and Drug Administration (FDA) is investigating potential negative side effects linked to GLP 1 diabetes drugs like Ozempic and Mounjaro, which include complications such as hair loss, suicidal thoughts, and difficulty breathing. Current information from the FDA shows that its Adverse Event Reporting System (FAERS) has received reports of patients experiencing symptoms such as alopecia, suicidal thoughts, and aspiration while on GLP 1 receptor agonists. The FDA is currently determining whether regulatory action is necessary.

Medications like Ozepmic, Mounjaro, Wegovy and Zepbound, which are GLP 1 receptor agonists, function by replicating the hormone GLP 1. This hormone triggers the secretion of insulin and may also cause a decrease in hunger. While initially sanctioned for diabetes treatment, these drugs are also frequently used for weight loss. Semaglutide, sold under the brand names Ozempic, Rybelsus, and Wegovy, is possibly the most recognized drug in this category.

Novo Nordisk, who holds exclusive patent rights to semaglutide, acknowledges that the most common side effects are gastrointestinal issues such as nausea, diarrhea, and constipation. The medicine guide for Ozempic lists additional possible side effects, including pancreatitis, kidney failure, hypoglycemia, and visual changes. Hair loss, depression, and aspiration are not currently listed as potential side effects.

When asked for a statement, Novo Nordisk confirmed awareness of the FDA's ongoing evaluation of the reported side effects. Six of its total products including Saxenda, Victoza, and Xultophy, were identified as potentially having these side effects. The company emphasized that just because a product appears on the FAERS list doesn't guarantee that the risk associated with the medication is real.

Novo Nordisk asserts that the approved product labels reflect the known risks of these drugs and reiterates its stand behind the safety and efficacy of its GLP 1RA medicines, provided they are used as indicated under the supervision of a licensed healthcare professional.